Skip to main content

Table 2 Subsequent second-line anticancer treatments in cohorts after sIPTW analysis

From: Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice

Treatments, n (%) Palbociclib + letrozole (n = 839) Letrozole alone (n = 698)
First-line treatment only* 448 (53.4) 233 (33.4)
Any second-line treatment received 391 (46.6) 465 (66.6)
 CDK4/6 inhibitor 165 (42.2) 292 (62.9)
 Chemotherapy 100 (25.6) 44 (9.4)
 Endocrine therapy alone 64 (16.4) 96 (20.7)
 Other anticancer treatments 88 (22.5) 56 (12.0)
  1. CDK4/6 cyclin-dependent kinase 4/6, sIPTW stabilized inverse probability of treatment weighting
  2. *Includes patients who continued treatment, died, or were censored in the first-line setting
  3. Patients could have received > 1 category of second-line treatment